Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 62.7% in November

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 152,900 shares, an increase of 62.7% from the October 31st total of 94,000 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average trading volume of 395,000 shares, the short-interest ratio is presently 0.4 days.

Entero Therapeutics Trading Up 4.3 %

NASDAQ:ENTO traded up $0.02 during midday trading on Friday, reaching $0.47. The company had a trading volume of 25,201 shares, compared to its average volume of 174,591. Entero Therapeutics has a 12-month low of $0.19 and a 12-month high of $14.51. The business’s fifty day simple moving average is $0.52.

Entero Therapeutics (NASDAQ:ENTO) last announced its quarterly earnings data on Monday, October 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. Equities analysts forecast that Entero Therapeutics will post -1.13 EPS for the current year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.